Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 4/2015

Open Access 01-10-2015 | Review Paper

Combining radiotherapy with sunitinib: lessons (to be) learned

Authors: Esther A. Kleibeuker, Matthijs A. ten Hooven, Henk M. Verheul, Ben J. Slotman, Victor L. Thijssen

Published in: Angiogenesis | Issue 4/2015

Login to get access

Abstract

To improve the efficacy of radiotherapy (RTx), there is a growing interest in combining RTx with drugs that inhibit angiogenesis, i.e., the process of neo-vessel formation out of preexisting capillaries. A frequently used drug to inhibit angiogenesis is sunitinib (Sutent, SU11248), a receptor tyrosine kinase inhibitor that is currently FDA approved for the treatment of several cancer types. The current review presents an overview of the preclinical studies and clinical trials that combined sunitinib with RTx. We discuss the findings from preclinical and clinical observations with a focus on dose scheduling and commonly reported toxicities. In addition, the effects of combination therapy on tumor response and patient survival are described. Finally, the lessons learned from preclinical and clinical studies are summarized and opportunities and pitfalls for future clinical trials are presented.
Appendix
Available only for authorised users
Literature
1.
Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 4:737–747CrossRefPubMed
2.
Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104:1129–1137CrossRefPubMed
3.
Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11:239–253CrossRefPubMed
4.
5.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62CrossRefPubMed
6.
Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13:3395–3402PubMedCentralCrossRefPubMed
7.
Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553–563PubMed
8.
McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng CY, Gaber MW et al (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76:1537–1545PubMedCentralCrossRefPubMed
9.
Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP et al (1998) Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686–5689PubMed
10.
Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, Dorfler A et al (2003) Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 23:3869–3876PubMed
11.
Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB (2008) SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 71:873–879CrossRefPubMed
12.
Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745CrossRefPubMed
13.
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed
14.
Aparicio-Gallego G, Blanco M, Figueroa A, Garcia-Campelo R, Valladares-Ayerbes M, Grande-Pulido E, Anton-Aparicio L (2011) New insights into molecular mechanisms of sunitinib-associated side effects. Mol Cancer Ther 10:2215–2223CrossRefPubMed
15.
Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G et al (2003) SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 63:4009–4016PubMed
16.
Zhang HP, Takayama K, Su B, Jiao XD, Li R, Wang JJ (2011) Effect of sunitinib combined with ionizing radiation on endothelial cells. J Radiat Res 52:1–8CrossRefPubMed
17.
El Kaffas A, Al-Mahrouki A, Tran WT, Giles A, Czarnota GJ (2013) Sunitinib effects on the radiation response of endothelial and breast tumor cells. Microvasc Res
18.
Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy DR, Dudek AZ (2008) Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone. Eur J Cancer 44:2506–2517CrossRefPubMed
19.
Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R (2012) Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 7:154PubMedCentralCrossRefPubMed
20.
Hillman GG, Singh-Gupta V, Al-Bashir AK, Yunker CK, Joiner MC, Sarkar FH, Abrams J et al (2011) Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl Oncol 4:110–121PubMedCentralCrossRefPubMed
21.
Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti C, Subramanian S et al (2011) Anti-angiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res
22.
Casneuf VF, Delrue L, van Damme N, Demetter P, Robert P, Corot C, Duyck P et al (2011) Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent. Radiat Res 175:10–20CrossRefPubMed
23.
Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G (2009) Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model. Ann Oncol 20:1703–1707CrossRefPubMed
24.
Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM, Baek KH, Waterman PR et al (2009) Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 74:1207–1216PubMedCentralCrossRefPubMed
25.
Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA et al (2011) Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 17:7337–7346PubMedCentralCrossRefPubMed
26.
Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, Lv T et al (2013) Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer Sci 104:1052–1061CrossRefPubMed
27.
Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT (2012) Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 72:638–648PubMedCentralCrossRefPubMed
28.
Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan N (2009) Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. Radiother Oncol 91:126–131PubMedCentralCrossRefPubMed
29.
Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A et al (2001) Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20:3266–3280CrossRefPubMed
30.
Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko JS et al (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129:2158–2170PubMedCentralCrossRefPubMed
31.
Dirkx AE, Oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L et al (2006) Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20:621–630CrossRefPubMed
32.
Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:6171–6180PubMedCentralCrossRefPubMed
33.
Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, Kreuger J et al (2015) VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J 29:227–238CrossRefPubMed
34.
Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol 38:90–97CrossRefPubMed
35.
Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A et al (2011) γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE 6:e28217PubMedCentralCrossRefPubMed
36.
Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX et al (2011) The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71:2488–2496PubMedCentralCrossRefPubMed
37.
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379–5388PubMedCentralCrossRefPubMed
38.
Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35CrossRefPubMed
39.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124CrossRefPubMed
40.
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16–24CrossRefPubMed
41.
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed
42.
Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC et al (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 115:3571–3580PubMedCentralCrossRefPubMed
43.
Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K et al (2012) Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE 7:e36979PubMedCentralCrossRefPubMed
44.
Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P (2008) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer 112:650–658CrossRefPubMed
45.
Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ et al (2008) An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res 14:5255–5259CrossRefPubMed
46.
Staehler M, Haseke N, Nuhn P, Tullmann C, Karl A, Siebels M, Stief CG et al (2011) Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma. BJU Int 108:673–678PubMed
47.
Staehler M, Haseke N, Stadler T, Nuhn P, Roosen A, Stief CG, Wilkowski R (2012) Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol 30:290–293CrossRefPubMed
48.
Choi YR, Han HS, Lee OJ, Lim SN, Kim MJ, Yeon MH, Jeon HJ et al (2012) Metastatic renal cell carcinoma in a supraclavicular lymph node with no known primary: a case report. Cancer Res Treat 44:215–218PubMedCentralCrossRefPubMed
49.
Hird AE, Chow E, Ehrlich L, Probyn L, Sinclair E, Yip D, Ko YJ (2008) Rapid improvement in pain and functional level in a patient with metastatic renal cell carcinoma: a case report and review of the literature. J Palliat Med 11:1156–1161CrossRefPubMed
50.
Basille D, Andrejak M, Bentayeb H, Kanaan M, Fournier C, Lecuyer E, Boutemy M et al (2010) Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy. Ann Pharmacother 44:383–386CrossRefPubMed
51.
Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, Choueiri TK (2010) Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. J Clin Oncol 28:e433–e435CrossRefPubMed
52.
Straka C, Kim DW, Timmerman RD, Pedrosa I, Jacobs C, Brugarolas J (2013) Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. J Clin Oncol 31:e401–e403CrossRefPubMed
53.
Venton G, Ducournau A, Gross E, Lechevallier E, Rochwerger A, Curvale G, Zink JV et al (2012) Complete pathological response after sequential therapy with sunitinib and radiotherapy for metastatic clear cell renal carcinoma. Anticancer Res 32:701–705PubMed
54.
Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G et al (2009) Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068–4075CrossRefPubMed
55.
George S, Blay JY, Casali PG, le Cesne A, Stephenson P, Deprimo SE, Harmon CS et al (2009) Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959–1968CrossRefPubMed
56.
Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA et al (2013) Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. Int J Radiat Oncol Biol Phys 86:540–545PubMedCentralCrossRefPubMed
57.
Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC, Mehta MP (2010) Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 78:188–193CrossRefPubMed
58.
Wuthrick EJ, Curran WJ Jr, Camphausen K, Lin A, Glass J, Evans J, Andrews DW et al (2014) A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 90:369–375CrossRefPubMed
59.
Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21:2529–2536CrossRefPubMed
60.
Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672CrossRefPubMed
61.
Balana C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, Capellades J et al (2014) Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. Target Oncol
62.
Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, Duerinck J et al (2011) Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 103:491–501CrossRefPubMed
63.
Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY et al (2014) A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. Br J Cancer 111:2254–2261CrossRefPubMed
64.
Wuthrick EJ, Kamrava M, Curran WJ Jr, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R et al (2011) A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer 117:5548–5559PubMedCentralCrossRefPubMed
65.
Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295–1304CrossRefPubMed
66.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751CrossRefPubMed
67.
Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ et al (2015) Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med (in press)
68.
Hagiwara M, Hackshaw MD, Oster G (2013) Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma. J Med Econ 16:1300–1306CrossRefPubMed
69.
Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P (2009) Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 124:1293–1300CrossRefPubMed
70.
Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A et al (2012) Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 18:3428–3439CrossRefPubMed
71.
Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M, Bamboat Z, Shia J et al (2011) Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 18:2192–2199PubMedCentralCrossRefPubMed
72.
Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S et al (2010) Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 28:21–28CrossRefPubMed
73.
Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V, Itti E et al (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 52:1048–1055CrossRefPubMed
74.
Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima K, Takiguchi M et al (2012) Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma. Int J Oncol 41:1593–1600PubMedCentralPubMed
75.
Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA et al (2012) Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 18:3961–3971PubMedCentralCrossRefPubMed
76.
Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL (2012) Combining angiogenesis inhibition and radiotherapy: a double-edged sword. Drug Resist Updat 15:173–182CrossRefPubMed
77.
Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL et al (2014) Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol 25:121–126PubMedCentralCrossRefPubMed
78.
Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG, DeLaney TF, Sahani DV (2015) CT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression. AJR Am J Roentgenol 204:W11–W18CrossRefPubMed
79.
Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Kamijo A, Akiba T et al (2015) Phase II study of preoperative concurrent chemoradiotherapy with S-1 plus bevacizumab for locally advanced resectable rectal adenocarcinoma. Oncology 88:49–56CrossRefPubMed
80.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed
81.
Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY, Vetto JT, Pommier RF et al (2013) Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res 19:6902–6911CrossRefPubMed
82.
Hottinger AF, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas MI, Hundsberger T et al (2014) Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 110:2655–2661PubMedCentralCrossRefPubMed
83.
Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF (2014) Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 88:1041–1047CrossRefPubMed
84.
Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, Zadeh G (2014) MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol 16:868–879PubMedCentralCrossRefPubMed
Metadata
Title
Combining radiotherapy with sunitinib: lessons (to be) learned
Authors
Esther A. Kleibeuker
Matthijs A. ten Hooven
Henk M. Verheul
Ben J. Slotman
Victor L. Thijssen
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 4/2015
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-015-9476-3

Other articles of this Issue 4/2015

Angiogenesis 4/2015 Go to the issue

Review Paper

The pathogenic role of angiogenesis in rheumatoid arthritis

Review Paper

Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward

Original Paper

Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease

Executive Summary

Executive summary of the 11th HHT international scientific conference

Original Paper

Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis

Original Paper

Metallothionein 2 regulates endothelial cell migration through transcriptional regulation of vegfc expression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits